Imatinib resistance in multidrug-resistant K562 human leukemic cells.
about
Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells.Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.Reversion of p-glycoprotein-mediated multidrug resistance in human leukemic cell line by diallyl trisulfideChemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNADrug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.Mechanisms of resistance to BCR-ABL kinase inhibitors.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line.Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients.Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.Long-chain polyunsaturated fatty acids promote paclitaxel cytotoxicity via inhibition of the MDR1 gene in the human colon cancer Caco-2 cell line.Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatinThe Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
P2860
Q33466143-8A2D77C5-2BA7-4F68-AB94-906CB3E845A1Q34209307-F9E96E3A-81D9-40D7-9A96-B835678BBD9EQ34787556-0D5A7CD3-9A67-4E16-B8B9-B6B946D085D8Q35946822-B30DAB3A-1146-441D-B9A5-060A87B3FA32Q35991845-F6AB9D08-D549-4824-BCB1-8972CAAFD81AQ36163183-0E692A75-EA4A-4E57-A058-7895255D3AD1Q36350221-930D3AA0-A720-48D9-BC47-0801FDFC9B96Q37634419-07125EEF-2AE6-4190-BE5E-865B084033BCQ37836923-543ACFB6-BF7B-4365-847E-6F7C7AEDE8DBQ38246305-FE86D276-2CBB-44A4-8119-8D3CB145512BQ38253243-343DD979-7FC6-4129-8A46-D1621D7E0EB9Q38797633-F6BFD761-E230-4C37-9BC8-287455DB45FAQ38857169-EA323909-3A1A-44B1-BDBE-D6A5FEFCF0E6Q38996487-3152E99C-98AE-486D-BAB4-E3044B6E5EF7Q39121828-BF32936E-2183-4725-9885-DE214FB6ED7AQ39440567-0A588338-EF79-4BC1-B53F-2E5E29CC6488Q39473872-D3F76CC0-52EB-4DE1-B529-CF11FC52CE66Q39710105-3B47DAB5-D94F-41AE-8D4E-F1DCCB2D04C9Q41842515-27F35A20-8FEF-485A-B98F-A4A5DCBE6A41Q47357292-4DDC85BC-B63D-4CC8-890F-8716642EF10C
P2860
Imatinib resistance in multidrug-resistant K562 human leukemic cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Imatinib resistance in multidrug-resistant K562 human leukemic cells.
@en
Imatinib resistance in multidrug-resistant K562 human leukemic cells.
@nl
type
label
Imatinib resistance in multidrug-resistant K562 human leukemic cells.
@en
Imatinib resistance in multidrug-resistant K562 human leukemic cells.
@nl
prefLabel
Imatinib resistance in multidrug-resistant K562 human leukemic cells.
@en
Imatinib resistance in multidrug-resistant K562 human leukemic cells.
@nl
P2093
P1433
P1476
Imatinib resistance in multidrug-resistant K562 human leukemic cells.
@en
P2093
Basilio A Kotsias
Fernanda Rubio
Georgina Coló
Mónica A Costas
Silvana del Mónaco
Yanina Assef
P304
P356
10.1016/J.LEUKRES.2008.09.024
P577
2008-11-01T00:00:00Z